Post Profile

Related Posts

Who’s Suing Novartis AG (ADR) (NVS), And Why?

Business & Finance / Investing : Insider Monkey

Would you hold a pharmaceutical product presentation in Hooters? That’s just one of many alleged instances that the U.S. government lists as reasons to sue pharmaceutical giant Novartis AG (ADR) (NYSE:NVS). The Justice Department an...

Novartis Hosts Scientific Symposium In Philippines To Review Research Approaches, Clinical Management, And Growing Presence Of Dengue

Health : Medical News Today

The Novartis Institute for Tropical Diseases (NITD) is hosting a global symposium in the Philippines, bringing world-renowned Dengue experts together to discuss critical issues facing Dengue treatment and prevention. The four-day sy...

Novartis AG (ADR) (NVS): Are Hedge Funds Right About This Stock?

Business & Finance / Investing : Insider Monkey

Novartis AG (ADR) (NYSE:NVS) was in 24 hedge funds’ portfolio at the end of March. NVS investors should be aware of an increase in support from the world’s most elite money managers lately. There were 19 hedge funds in our database ...

Novartis AG (NVS) Dividend Stock Analysis

Business & Finance / Investing : Dividend Growth Investor

Novartis AG (NVS), through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Novartis is an international dividend achiever, has paid uninterrupted dividends on its ...

A Look at Novartis AG (ADR) (NVS)’ Second Quarter

Business & Finance / Investing : Insider Monkey

The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company’s net sales were up 1%, and EPS was down 6% year over year. Novartis AG (ADR) (NYSE:NVS) managed to narrowly beat Wall...


Copyright © 2016 Regator, LLC